No abstract is provided for this article.
AbstractRecent advances in molecular cloning and gene-expression techniques have led to the identification and characterization of many G protein-coupled receptors, including new subtypes and sub-subtypes of previously identified receptors. With the dramatic increase in the number of these receptors, the technique of in situ hybridization (ISH) has become an essential addition to the tools available for receptor research.KeywordsDextran SulfateYeast tRNANucleic Acid ProbeUridine TriphosphateStandard Sodium CitrateThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
<b>Introduction and background.</b> The protein deacetylase SIRT1 is an anti-ageing molecule that is down-regulated in chronic obstructive pulmonary disease (COPD). SIRT1 maintains genomic stability and regulates antioxidant genes, and its function is known to be controlled by SIRT1 shuttling between nuclei and cytoplasmic fraction. <b>Aims and objectives.</b> We investigated the molecular dynamics of SIRT1 after exposure of airway epithelial cells to cigarette smoke extract (CSE). <b>Methods and results.</b> In primary bronchial epithelial cells (monolayer and air-liquid interface) and BEAS-2B cell line, SIRT1 was located predominantly in cytoplasmic fraction, but a single dose of CSE induced dynamic SIRT1 shuttling from cytoplasm to the nucleus, mainly through the activation of phosphatidylinositol 3-kinase-α (PI3Kα). Such SIRT1 nuclear shuttling strongly induced the antioxidant superoxide dismutase-2 (SOD2) mRNA, thus protecting against oxidative stress. However, when BEAS-2B cells were primed with the repeated CSE exposure, CSE-inducedSIRT1 shuttling and resultant SOD2 mRNA induction were significantly impaired, which was mimicked by treatment with a SIRT1 inhibitor sirtinol. <b>Conclusions.</b> Our results suggest that recurrent cigarette smoke exposure potentially impairs SIRT1 shuttling in bronchial epithelial cells, resulting in reduced protection against exogenous oxidative stress.
The presence of thrombus is associated with adverse clinical outcomes. Our aim was to develop a classification of thrombus burden (TB) in patients with ST-segment elevation myocardial infarction (STEMI).We retrospectively analyzed 900 consecutive patients treated with percutaneous coronary intervention for STEMI. Drug-eluting stents were used in 90.1%. TB was graded (G) as G0 = no thrombus, G1 = possible thrombus, G2 = small [greatest dimension ≤ 1/2 vessel diameter (VD)], G3 = moderate (> 1/2 but < 2VD), G4 = large (≥ 2VD), G5 = unable to assess TB due to vessel occlusion. Patients with G5 were reclassified to a thrombus category after flow achievement either with a guidewire or a small (1.5 mm) balloon. The incidence of major adverse cardiac events (MACE) - defined as death, myocardial infarction and infarct-related artery revascularization - was computed using the Kaplan-Meier method.Median duration of follow-up was 18.5 months. G5 patients constituted 57.7% of all patients and reclassification was achieved in 97.9%. TB after reclassification was G0, 8.1%; G1, 19%; G2, 24.5%, G3,16.6%, G4, 30%, G5, 1.9%. The 2-year cumulative MACE-free survival was comparable in G1, G2, G3 (84.5%, 85.9% and 87% respectively, p = 0.83), while G0 (75.8%) and G4 (75%) did significantly worse (p = 0.001). After stratification in two groups of small (G0-3) and large (G4) TB, the latter was found to be an independent predictor for 2-year mortality (HR: 1.66, 95% CI: 1.04-2.68, p = 0.035) and MACE rate (HR: 2.04, 95% CI: 1.44-2.88, p < 0.001).In patients with STEMI, TB can be reliably estimated in occluded infarct-related arteries. Large thrombus (≥ 2 VD) is a significant independent predictor for mortality and MACE.
Drugs currently available or under development for the treatment of chronic obstructive pulmonary disease (COPD) are reviewed. More research on the basic cellular and molecular mechanisms of COPD and emphysema is urgently needed to aid the logical development of new treatments for this common and important disease for which no effective preventative treatments currently exist. There is a major need to develop new treatments for chronic obstructive pulmonary disease (COPD), as no currently available drug therapy reduces the relentless progression of the disease. In particular, there is a need to develop drugs that control the underlying inflammatory and destructive processes. There have been few therapeutic advances in the drug treatment of COPD, in contrast to the enormous advances made in asthma management which reflect a much better understanding of the underlying disease.1–3 Although COPD is commonly treated with drugs developed for asthma, this is often inappropriate as the inflammatory processes in the two conditions differ markedly.4,5 Recognition of the global importance and rising prevalence of COPD and the absence of effective treatments has now led to a concerted effort to develop new drugs for this disease.6,7 Rational treatment depends on understanding the underlying disease process and there have been recent advances in understanding the cellular and molecular mechanisms that may be involved. COPD involves a chronic inflammation in the small airways and lung parenchyma with the involvement of neutrophils, macrophages, and cytotoxic (CD8+) T lymphocytes. This inflammation results in fibrosis with narrowing of the small airways (chronic obstructive bronchitis) and lung parenchymal destruction due to the action of various proteases such as neutrophil elastase and matrix metalloproteinases (emphysema). This inflammation is quite different from that seen in asthma, indicating that different treatments are likely to be needed.4 There are several reasons why drug …
Abstract Early secreted antigenic target of 6 kD (ESAT-6) is a M. tuberculosis protein that induces protective immunity against tuberculosis in animal models and is a putative vaccine candidate. However, this protein also contributes to virulence and inhibits immune cells activation. In this study, we evaluated the effects of ESAT-6 on the function of human dendritic cells. Immature dendritic cells (DC) were induced from monocytes cultured with GM-CSF plus IL-4. ESAT-6 inhibited IL-12, but promotes IL-23 production of DC during maturation stimulated by LPS plus CD40L. This is correlated with downregulated IL-12p35 and upregulated IL-23p19 transcripts, respectively. ESAT-6 did not affect the induction of TNF-α, IL-6 and IL-8 from DC during maturation. ESAT-6 also inhibited upregulation of co-stimulatory molecules, CD80, CD86, HLA-DR, in both monocyte derived DC and myeloid DC freshly purified from human blood, in response to stimulation of LPS plus CD40L. DC pretreated with ESAT-6 induced less IL-2 and IFN-γ production in mixed lymphocyte reactions, and stimulated less IFN-γ, but more IL-17 production from M.tuberculosis responsive T cells compared to nontreated DC. Blocking TLR1/2 on DC or removing 20 amino acids in C-terminus did not ablate the inhibition of ESAT-6 on IL-12 production. We conclude that ESAT-6 enhances IL-23 production at the expense of IL-12 in a TLR2 independent mechanism, which favors Th17 over Th1 activation. (Supported by the NIH grants AI082335 and AI063514)
No abstract is provided for this article.
No abstract is provided for this article.
Current therapies for COPD fail to prevent disease progression or mortality. The mainstay of current drug therapy is long-acting bronchodilators; several longer-acting inhaled β2-agonists and muscarinic antagonists (and combinations) are now in development. No treatments have so far been shown to suppress chronic inflammation in COPD lungs. With better understanding of the inflammatory and destructive process in the pathophysiology of COPD, several new therapeutic targets have been identified. Several mediator antagonists tested in COPD have so far been disappointing, but CXCR2 antagonists that block pulmonary neutrophil and monocyte recruitment may be more promising. Broad-spectrum anti-inflammatory drugs may be more effective and include inhibitors of the enzymes phosphodiesterase-4, p38 mitogen-activated protein kinase, NF-κB kinase and PI3 kinase-γ and PI3 kinase-δ, but side effects will be a major limitation with systemic administration, so that inhaled delivery may be necessary. Perhaps the most promising approach is reversal of corticosteroid resistance through increasing histone deacetylase-2 (HDAC2) activity. This might be achieved by theophylline-like drugs, selective PI3 kinase-δ inhibitors, more effective antioxidants and nonantibiotic macrolides.